Thyme Care Raises $125 Million in Series E Funding at Over $2 Billion Valuation
Thyme Care has secured a $125 million funding round led by Morgan Health and supported by investors including Humana, CVS Health Ventures, AlleyCorp, HealthQuest Capital, and a16z Bio + Health. The investment values the cancer care startup at over $2 billion, doubling its valuation from just under a year ago during its Series D round. The company provides virtual navigation services to help patients manage their complex treatment journeys in oncology. It now plans to form a new parent entity called Thyme Companies to expand into additional areas of cancer care delivery and affordability challenges. Robin Shah, co-founder of Thyme Care, will serve as executive chairman of the new organization. Thyme Care’s services are available across all 50 U.S. states and reach over 10.5 million people annually. The company managed more than $7 billion in oncology spend last year and reported revenue exceeding $125 million — a fivefold increase from the prior year.
Topics: healthcare oncology startup funding